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OBJECTIVE—Experimental data from animal studies indicate
that portal vein glucose sensors play a key role in the responses
to slow-fall hypoglycemia. However, their role in modulating
these responses in humans is not well understood. The aim of the
present study was to examine in humans the potential role of
portal vein glucose sensors in physiological responses to insulin-
induced hypoglycemia mimicking the slow fall of insulin-treated
diabetic subjects.
RESEARCH DESIGN AND METHODS—Ten nondiabetic sub-
jects were studied on two different occasions during intravenous
insulin (2 mU  kg
1  min
1) plus variable glucose for 160
minutes. In both studies, after 60 min of normal plasma glucose
concentrations, hypoglycemia (47 mg/dl) was induced slowly (60
min) and maintained for 60 min. Hypoglycemia was preceded by
the ingestion of either oral placebo or glucose (28 g) given at 30
min.
RESULTS—Plasma glucose and insulin were not different with
either placebo or glucose (P  0.2). Similarly, counterregulatory
hormones, substrates, and symptoms were not different with
either placebo or glucose. The Stroop color and colored words
subtest of the Stroop test deteriorated less (P  0.05) with
glucose than placebo.
CONCLUSIONS—In contrast to animals, in humans, prevention
of portal hypoglycemia with oral glucose from the beginning of
insulin-induced slow-fall hypoglycemia has no effect on sympa-
thoadrenal and symptomatic responses to hypoglycemia.
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t has been suggested that glucose sensors in the
portal area are necessary to monitor glucose derived
from the gut (1). In fact, when exogenous glucose is
infused directly in the portal vein (2,3) or in the
duodenum (4) or ingested orally as glucose load (5–7), a
portal-arterial glucose gradient is generated with glucose
concentrations higher in the portal vein than in arterial
circulation. Such portal-arterial glucose gradient generates
a portal signal that is probably dependent on glucose-
sensitive nerves in the portal veins, the ﬁring rate of which
is inversely proportional to the portal glucose concentra-
tion (8). The signal then moves through the hepatic vagal
afferences to modulate the function of different tissues
(e.g., liver, pancreatic -cells) involved in the control of
glucose homeostasis (9). In addition, signals enter the
central nervous system to regulate hypothalamic func-
tions, such as feeding and satiety (10). Recent evidence
indicates that GLUT2 transporter is essential for glucose
sensing by the portal glucose sensor (11,12) and also that
glucagon-like peptide 1 (GLP-1) receptor is required for
the function of the portal glucose sensor in mice (9).
Earlier studies in animals have shown that portal-
arterial glucose gradient is involved in the control of
intake of food (10) and stimulation of net hepatic glucose
uptake (2,13). In addition, portal glucose sensors modulate
the sympathetic responses to hypoglycemia (14,15). How-
ever, how portal glucose sensors may affect sympathetic
responses to hypoglycemia and how their activity inte-
grates with that of glucose-sensitive areas in the brain is
not well understood (16). In fact, several studies in ani-
mals indicate that the brain is the prominent center for the
sensing of hypoglycemia. In dogs in which insulin-induced
hypoglycemia was allowed to occur peripherally while
brain euglycemia was maintained by glucose infusions in
carotid and vertebral arteries bilaterally, the responses of
counterregulatory hormones decreased nearly completely
compared with dogs with brain neuroglycopenia (17,18).
In rats, the ventromedial hypothalamus (VMH) appears to
be necessary to trigger counterregulation during hypogly-
cemia. In fact, bilateral lesions of the VMH in conscious
rats suppresses glucagon and catecholamine responses
during hypoglycemia (19,20), suggesting that the VHM is
one of the most important sites acting as a glucose sensor
(21,22). However, there is evidence that in rats, activation
of portal glucose sensors by glucose may be the most
important modulators of sympathetic response to hypogly-
cemia, resulting in a signiﬁcant suppression of this re-
sponse (23–25).
Recent studies in rats have established that portal vein
glucose sensors, responsible for hypoglycemic detection,
extend beyond the portal vein being placed also in the
superior mesenteric vein and that their role is essential in
detecting slow, but not fast, fall in blood glucose (26).
Limited knowledge is available about the potential role
of portal glucose sensors in humans. Only three studies
(5–7) have addressed the question, with conﬂicting results.
In fact, counterregulatory hormone responses to hypogly-
cemia have been found potentiated (5), reduced (6), or
reduced in early phase and potentiated in late phase (7)
after ingestion of oral glucose (5,6) or orange juice (7). It
is likely that methodological differences account, at least
in part, for these divergent results.
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194 DIABETES, VOL. 58, JANUARY 2009So far, no study has investigated in humans the role of
portal glucose sensors on counterregulation, symptoms,
and cognitive function during hypoglycemia induced
slowly, to mimic the hypoglycemia of the clinical situation
(27). It is worthy of note that in the postprandial state, a
condition characterized by glucose arriving in the portal
vein from the gut, sympathetic responses and some as-
pects of cognitive function are affected by the rate of fall
of blood glucose (27). However, in the postprandial con-
dition, it is not only glucose that enters in the portal
system but also other substrates that may suppress sym-
pathoadrenal responses to hypoglycemia (28).
The aim of the present study was to examine in humans
the potential effects of portal glucose sensors on hormonal
counterregulatory responses and responses of symptoms
and cognitive function in a model of slow-fall insulin-
induced hypoglycemia. For this purpose, healthy subjects
were studied during hypoglycemia preceded by ingestion
of either oral glucose to prevent portal hypoglycemia or
placebo.
RESEARCH DESIGN AND METHODS
Institutional review board approval was obtained for these studies. Ten
healthy nondiabetic volunteers (ﬁve men, age 30  5 years, BMI 22  1.5
kg/m
2, means  SD) were studied. The study was carried out according to the
Helsinki Declaration after obtaining written informed consent by all subjects.
All subjects were studied on two different occasions in a random order,
computer-generated sequence, at 2- to 3-week intervals, with the hyperinsu-
linemic-hypoglycemic glucose clamp technique. Both subjects and investiga-
tors were blind to treatments.
On the morning of the studies, subjects were admitted to the general
clinical research center of the Department of Internal Medicine at 0700 h. A
hand vein of the nondominant arm was cannulated retrogradely and main-
tained in a hot box (60°C) for sampling of arterialized-venous blood (29). A
superﬁcial vein of the ipsilateral arm was also cannulated for infusion of
insulin using a syringe pump (Harvard Apparatus, Ealing, South Natick, MA)
and glucose (see below). The two veins were maintained patent by means of
0.9% NaCl infusion (0.5 ml/min).
At time 0900 h (time 0 min), intravenous insulin at the rate of 2 mU  kg
1
 min
1 was started and continued until the end of the study (i.e., 160 min).
Intravenous glucose at variable rate was also infused. Plasma glucose was
allowed to decrease over a period of 60 min from 60 min to the target plasma
glucose of 47 mg/dl at 120 min. This hypoglycemic plateau was maintained for
the next 40 min, that is, until the end of the study.
On one occasion, at time 0930 h (time 30 min), subjects ingested a 150-ml
drink containing either glucose (28 g) or a seemingly identical placebo
containing aspartame (1 g). All drinks were prepared and administered by a
research nurse not involved in the further execution of the study.
Pilot study results indicated that plasma glucose would increase by 10–15
mg/dl in the following 30 min after ingestion of 28 g glucose. To maintain the
double-blind design of the study, glucose infusions rates were varied from 30
to 60 min to produce increments in the magnitude of 10–15 mg/dl in both
study conditions.
In all studies, blood samples were drawn at 5- to 10-min intervals for
bedside plasma glucose measurement and at 30-min intervals for measure-
ment of plasma insulin, C-peptide, pancreatic polypeptide, counterregulatory
hormone, and nonglucose substrate concentrations.
A semiquantitative symptom questionnaire (30) was administered every 30
min. Subjects were asked to score from 0 (none) to 5 (severe) on each of the
following symptoms: seven autonomic/neurogenic (adrenergic: heart pound-
ing, tremor, anxiety, and irritability; cholinergic: sweating, hunger, and
tingling), ﬁve neuroglycopenic (difﬁculty in thinking, weakness, dizziness,
blurred vision, and drowsiness), and three nonspeciﬁc (thirst, nausea, and
headache) (31). The sum of each of these constituted the total symptom score.
In addition, at baseline, before inducing hypoglycemia, and at the hypogly-
cemic plateau (indicated as time 30, time 0, and time 120), cognitive function
was assessed by applying a battery of hypoglycemia-sensitive tests: Trail
making A and B tests (32), verbal ﬂuency (33), verbal memory test (33), digit
vigilance test (33), forward and backward digit span (34), Stroop word, color,
and color-word (interference) subtests (35), and paced auditorial serial
addition test (PASAT 2 and 3 s) (36), with tests always performed in this order.
The whole battery took 30 min to complete and was, therefore, suitable for
repeated administration. All tests presented were paper-based except PASAT,
which was presented on an audiocassette tape to control the rate of stimulus
presentation. Each subject practiced these tasks on each study occasion, i.e.,
before the commencement of the glucose clamp, until stable performance was
achieved; in addition, to prevent any learning/practice effects, two alternate
forms of each test were prepared and used.
Analytical methods. Plasma glucose was measured by means of a Beckman
glucose analyzer (Glucose Analyzer II; Beckman Instruments, Fullerton, CA).
Plasma insulin, C-peptide, pancreatic polypeptide, counterregulatory hor-
mone, glucagon, adrenaline, norepinephrine, glycerol, -OH-butyrate, lactate,
and alanine were measured by previously described assays (37). Serum
ghrelin concentrations were measured using a commercial radioimmunoassay
kit (Phoenix Pharmaceuticals, Phoenix, AZ) that uses
125I-labeled bioactive
ghrelin as tracer and a rabbit polyclonal antibody against full-length octanoy-
lated human ghrelin. The assay detects both ghrelin and des-octanoyl-ghrelin.
The sensitivity of the assay is 30 pg/ml. The intra- and interassay CVs are 5
and 14%, respectively. Plasma free fatty acid (FFA) concentration was
measured using a commercial kit (Wako NEFA C test kit; Wako Chemicals,
Neuss, Germany).
Statistical analysis. Study conditions (placebo vs. glucose), time, and study
by time interactions for values measured repeatedly over time were assessed
by repeated-measures ANOVA with Huynh-Feldt adjustment for nonsphericity
when appropriate (38). Post hoc comparisons (Newman-Keuls test) were
carried out to pinpoint speciﬁc differences on signiﬁcant interaction terms.
A modiﬁed Bonferroni procedure (39) for multiple cognitive test adjust-
ments was used to maintain an overall type 1 error rate of 5% (0.05).
The sample size calculations were based on the hypothesis of a 30%
difference in adrenaline response (primary endpoint) between treatments. A
sample size of 10 subjects achieves 80% power to detect a difference of 30%
between treatments with an estimated SD of 30% and with a signiﬁcance level
() of 0.05 using a two-sided paired t test.
Data are given as means  SE, except where SD is speciﬁed. We
considered differences to be statistically signiﬁcant if the P value was 0.05 or
less. We conducted the statistical analyses using NCSS 2007 and PASS 2005
software (NCSS, Kaysville, UT).
RESULTS
Plasma glucose, C-peptide, and insulin concentra-
tions and rates of glucose infusion. In both study
conditions, plasma glucose was maintained at euglycemia
for 30 min by variable infusion of glucose. Thereafter,
similar increments were produced from 30 to 60 min in
both study conditions, and then the rate of glucose infu-
sion was decreased to reduce plasma glucose concentra-
tion to the target hypoglycemic plateau of 47  1.2 mg/dl
at 120 min. Subsequently, plasma glucose concentration
was maintained at the nominal plateau of 47 mg/dl for 40
min until the end of the studies with no differences
between study conditions (P  0.2). The calculated rate of
fall of plasma glucose from euglycemia (60 min) to ﬁrst
hypoglycemic plateau point (120 min) was 0.76  0.05 mg
 dl
1  min
1 in subjects given glucose and 0.65  0.05 in
those given placebo (P  0.106) (Fig. 1). Plasma C-peptide
concentrations decreased at 30 min in both studies. How-
ever, at 60 min, plasma C-peptide concentration increased
in the glucose study (1.3  0.4 nmol/l), whereas it contin-
ued to decrease in the placebo study (0.5  0.1 nmol/l, P 
0.035). Thereafter, plasma C-peptide concentrations de-
creased in both studies, although, on average, they were
higher in subjects given glucose than in those given
placebo (0.66  0.2 and 0.34  0.1 nmol/l, respectively,
P  0.04). Plasma insulin concentrations was similar in
placebo and glucose studies (188  4 and 181  6 	U/ml,
respectively, P  0.2). The rates of glucose infusion were
lower in the glucose compared with the placebo study
(5.7  0.4 vs. 2.8  0.4 mg  kg
1  min
1, respectively, P 
0.001).
Plasma glucagon, norepinephrine, adrenaline, pan-
creatic polypeptide, cortisol, and growth hormone
concentrations. After an initial decrease at 60 min in
both studies, plasma glucagon concentrations increased to
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0.001) in the placebo and to 143  17 pg/ml (vs. baseline
66  4.6 pg/ml, P  0.001) in the glucose study (Fig. 2).
These differences were not statistically signiﬁcant (P 
0.02). Plasma pancreatic polypeptide concentration in-
creased both during placebo and glucose studies with no
difference between studies (peak response 155  20 and
166  18 pmol/l, respectively, P  0.2). Plasma adrenaline
levels were not different between glucose and placebo
studies (peak response 4  0.9 and 3.7  1.0 nmol/l,
respectively, P  0.271). Similarly, plasma norepinephrine
concentrations increased in both placebo and glucose
studies with no difference between studies. Responses of
plasma cortisol were not different between studies (peak
response 16.2  3.7 and 15.5  2.6 	g/dl, respectively, P 
0.2). Plasma growth hormone increased more in response
to glucose than to placebo, although the difference was not
statistically signiﬁcant (P  0.107). Plasma ghrelin concen-
trations (data not shown) decreased over time from basal
to nadir values during the hypoglycemic plateau (from
268  32 to 172  19 pmol/l, P  0.018, and from 252  16
to 185  19 pmol/l, P  0.034, placebo and glucose studies,
respectively) with no difference between study conditions
(P  0.2).
Plasma nonglucose substrate. Plasma FFA levels de-
creased with no difference between studies (68  5 and
84  12 	mol/l in placebo and glucose studies, respec-
tively, P  0.2). Similarly, plasma glycerol and -OH-
butyrate concentrations decreased from baseline with no
difference between placebo and glucose studies (Fig. 3).
Plasma lactate concentrations increased in both studies.
The ﬁrst similar increment was observed at 60 min, and
then a further increase was detected at 140 min with no
difference between studies (P  0.075). Plasma alanine
concentrations were similar during placebo and glucose
studies (366  45 and 369  29 	mol/l, respectively, P 
0.2).
Symptoms. Symptom scores increased during hypoglyce-
mia during both placebo and glucose studies. However,
mean and peak values for total, autonomic, neuroglyco-
penic, adrenergic, and cholinergic symptom scores were
not different between studies (P  0.2 for all comparisons)
(Fig. 4).
Cognitive function. With the exception of digit vigilance
test, all cognitive tests deteriorated signiﬁcantly during
hypoglycemia both in placebo and glucose studies (Table
1). The Stroop color and colored words subtest deterio-
rated less in the glucose study than in the placebo study
(P  0.05).
DISCUSSION
The present study was undertaken to examine the effects
of portal glucose on the counterregulatory, symptomatic,
and cognitive responses to slow-fall hypoglycemia in hu-
mans after concomitant ingestion of either glucose to
prevent portal hypoglycemia while maintaining systemic
hypoglycemia or placebo. The results indicate that preven-
tion of portal hypoglycemia by oral glucose did not have
any impact on counterregulatory and symptomatic re-
sponse to hypoglycemia. Thus, this study supports the
view that in nondiabetic subjects, it is systemic glucose
sensing (i.e., the brain) that plays the key counterregula-
tory role when plasma glucose decreases (16). However,
oral glucose affected responses of -cells of pancreatic
islets, as shown by the greater response of C-peptide. In
addition, oral glucose preserved some aspects of cognitive
function during hypoglycemia, such as mental ﬂexibility
and attention.
It has been suggested that glucose sensors localized in
the portal vein modulate sympathoadrenal responses to
hypoglycemia in rats (14) and dogs (15). In these animals,
the increase in portal glucose levels, by infusing glucose
directly in the portal vein, in the face of systemic hypogly-
cemia, causes a net suppression of the sympathoadrenal
response, which is, instead, normally observed when hy-
poglycemia is allowed to occur in the portal vein (14,15).
Interestingly, recent studies in rats indicate that there
are glucose sensors in the superior mesenteric vein (25), in
addition to the portal vein, and that they play an essential
role in sensing slow, but not fast, fall in blood glucose
deﬁned as rate of decrease of 1.6 and 3.78 mg  dl
1 
min
1, respectively (26). In humans, it has been shown
m
g
/
d
l
40
50
60
70
80
90
100
110
Hypo-P
Hypo-G
µ
U
/
m
l
0
50
100
150
200
250
Time (min)
-30 -15 0 15 30 45 60 75 90 105120 140 160
m
g
/
k
g
/
m
i
n
0
2
4
6
8
10
12
Plasma Glucose
Plasma  Insulin
Glucose Infusion Rate
C- peptide
n
m
o
l
/
l
0.0
0.5
1.0
1.5
2.0
Oral glucose 28 g 
or placebo
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196 DIABETES, VOL. 58, JANUARY 2009that in postprandial conditions (27), when portal glucose
levels are higher than those in systemic circulation, re-
sponses to hypoglycemia are affected by the rate of fall of
glucose. Speciﬁcally, the sympathoadrenergic response
was greater in slow compared with fast fall of blood
glucose, whereas cognitive function deteriorated more
during fast fall of blood glucose. Notably in humans, slow
and fast fall are usually at rates of 0.6 and 1.8 mg  dl
1 
min
1, respectively (27). However, under those condi-
tions, the relative contribution of glucose and of other
nutrients cannot be separated. Therefore, we carried out
the present study by inducing hypoglycemia (47 mg/dl)
slowly, over 60 min at the rate of 0.75 mg  dl
1  min
1
(slow fall) and maintaining the hypoglycemic plateau for
an additional 40 min. Because the rate of fall in our study
was slower compared with that achieved in rats (1.6 mg
 dl
1  min
1) (26) in which slow-fall but not fast-fall
hypoglycemia had effects, it is concluded that in humans
the portal glucose sensors do not play a major counter-
regulatory role in the clinical situation in contrast to rats.
The oral load (28 g) was given before hypoglycemia,
which was allowed to occur slowly. As a consequence,
from the beginning of hypoglycemia the portal vein was
exposed to high glucose levels arriving from the intestine.
Most likely, elevation of portal plasma glucose prevented
activation of portal sensors during systemic hypoglycemia.
If portal glucose sensors had a prominent role in modu-
lating the sympathoadrenal response, we should have
observed a suppression of this response compared with
placebo, as described in animals (14,15). However, that
was not the case. Likely, species differences account for
the different ﬁndings in the present study in humans
compared with previous study in rats (26).
In the present study, sympathoadrenal responses, adren-
aline and norepinephrine, were not different after oral
glucose compared with placebo. In addition, we did not
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on the other counterregulatory hormones, such as gluca-
gon, cortisol, and growth hormone. Plasma concentrations
of ghrelin, a potent stimulator of growth hormone secre-
tion (40,41), were similarly suppressed during insulin-
induced hypoglycemia in both study conditions. Ghrelin
decreases during insulin-induced hypoglycemia, being in-
hibited by hyperinsulinemia (42). Although oral glucose is
a further mechanism of ghrelin inhibition (43), likely
hyperinsulinemia was the main determinant of its suppres-
sion. Finally, it is interesting to note that, according to
plasma ghrelin levels, the hunger symptom, which has
been shown to increase after ghrelin administration (44),
in our study was not different under both hypoglycemic
conditions.
The greater plasma C-peptide levels observed after oral
glucose might suggest that greater insulin levels have
occurred in the portal area in the face of identical periph-
eral arterial plasma insulin concentrations. This is likely to
be explained both by the slight increase in arterial plasma
glucose after oral glucose and by incretin effects mediated
mostly by GLP-1 release (45). Certainly GLP-1 favored
insulin secretion in the portal vein. However, the relative
contribution to portal hyperinsulinemia of GLP-1 and of
the oral glucose per se cannot be inferred from our study.
Although we did not measure GLP-1, its glucose-indepen-
dent stimulation of insulin secretion after ingestion of
glucose is well known (45).
GLP-1 has been found to suppress glucagon in healthy
subjects under euglycemic (46) but not during hypoglyce-
mic conditions (47). Because in our study glucagon levels
were similar with oral glucose and placebo, it is likely that
any inhibitory effect of GLP-1 on glucagon secretion was
offset by the predominant stimulatory effects of systemic
hypoglycemia achieved during the clamp procedure.
In line with counterregulatory hormone responses,
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glucose, in contrast to results previously reported by
Smith et al. (6). However, we did ﬁnd better preservation
in the color and color-words subtests of the Stroop test.
This ﬁnding is intriguing. Speculatively, it might be related
to neuroprotective effects of GLP-1 (48), although periph-
eral infusion of GLP-1 during stepped hypoglycemic
clamps does not alter cognitive function in healthy sub-
jects (47). However, these results do not negate a possible
effect related to portal increments of GLP-1 and its involve-
ment in the generation of neuroprotective portal signals
capable of modulating aspects of cognitive function.
One important limitation of our study is that we have no
direct measurement of portal vein glucose and do not
know with absolute certainty the degree of portal glucose
elevation achieved after oral glucose. Therefore, the con-
clusions of the present study that portal vein glucose
sensors do not play a role in hypoglycemia in humans rely
entirely on the assumption that oral glucose prevented
hypoglycemia in the portal vein in our experimental model
during the slow fall of blood glucose (60–120 min) and
during clamped hypoglycemia (120–160 min). We believe
that this was the case for the following reasons. In fact,
Smith et al. (6) have shown that the ingestion of 20 g
glucose labeled with the tracer [U-
13C6]glucose is fully
absorbed in a parabolic manner over 2 h in humans.
Based on this ﬁnding, it is conceivable that in our study, in
which a larger amount of oral glucose was given (28 g),
portal hypoglycemia was prevented, both during the pe-
riod of time of the slow fall of blood glucose (for 60 min)
and during the stable hypoglycemic plateau (additional 40
min). In addition, and most importantly, the lower amount
of glucose infused during hypoglycemia in the oral glucose
study compared with placebo represents a compensation
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in the portal vein and in the systemic circulation. Thus, it
is conceivable that the difference in glucose infusion rates
(GIRs) between the two studies represents a reliable
estimate of intestinal absorption of glucose, ultimately
elevating portal glucose. Based on the Smith et al. calcu-
lation of the rate of systemic absorption of the oral glucose
from the intestine, assuming absorption over 130 min and
a portal blood ﬂow of 0.8 l/min, it is possible to estimate
that the administration of 28 g glucose in our study
increased the venous portal glucose by a mean of 25
mg/dl, achieving a concentration of 72 mg/dl against a
systemic glucose concentration of 47 mg/dl. An alternative
approach to such an estimate is based on the following
considerations: subjects were hyperinsulinemic and hypo-
glycemic, with identical plasma insulin, glucose, and coun-
terregulatory hormone concentrations both in the placebo
and the glucose experiments of our study. Although we did
not measure glucose ﬂuxes, most likely under these cir-
cumstances, endogenous glucose production and glucose
utilization were equivalent in the placebo and the glucose
experiments. As a consequence, the difference in the GIRs
(GIR placebo  GIR glucose, 
GIRP-G) may represent a
good estimate of the glucose appearance rate from the gut
into systemic circulation. Although some of 
GIRP-G could
represent glucose that was initially taken up by the liver
and subsequently released, studies using oral ingestion of
labeled glucose suggest that this process is quantitatively
small (49–51). On these grounds, it is possible to achieve
an estimate of portal glucose level by dividing the differ-
ence in 
GIRP-G by the average portal plasma ﬂow (as-
sumed to be 10 ml  min
1  kg
1), resulting in an
estimated mean portal glucose elevation of 29 mg/dl that
corresponds to 20–22 mg/dl after adjusting for the amount
of glucose that might be used by other tissues (i.e., gut and
erythrocytes) of 25–30%. The above two independent
calculations yield similar conclusions, i.e., the oral glucose
administration in the present study successfully met the
goal of prevention of portal hypoglycemia during systemic
hypoglycemia.
TABLE 1
Cognitive tests scores during clamped hypoglycemia both with placebo and oral glucose ingestion
30 min 0 min 160 min
P
Study
(placebo vs. glucose) Time Study  time
Nominal plasma glucose (mg/dl) 90 90 47
Trail-making A*
Placebo 38.7  2.6 33.8  4.8 69.6  12 0.372 0.002 0.367
Glucose 34.2  3.1 36.4  3.3 59.0  3.8
Trail-making B*
Placebo 54.0  2.2 56.0  7.6 74.0  6.6 0.304 0.001 0.327
Glucose 52.8  5.2 55.4  5.1 84.3  7.4
PASAT (3 s)†
Placebo 56.2  0.4 56.3  0.3 51.0  1.7 0.101 0.001 0.576
Glucose 57.3  0.5 57.0  0.4 53.0  0.7
PASAT (2 s)†
Placebo 43.0  3 43.4  3.4 39.0  2.9 0.168 0.001 0.737
Glucose 46.7  0.8 47.5  1.0 43.5  0.4
Digit span forward‡
Placebo 4.8  0.2 5.0  0.3 4.3  0.3 0.385 0.009 0.853
Glucose 4.6  0.3 4.8  0.2 4.2  0.3
Digit span back.‡
Placebo 4.8  0.1 4.7  0.1 4.0  0.3 0.411 0.000 0.852
Glucose 4.6  0.3 4.6  0.3 3.9  0.2
Digit vigilance§
Placebo 35.7  1.2 35.5  1.2 36.5  1.0 0.303 0.284 0.196
Glucose 35.9  3.7 40.4  2.4 38.6  2.1
Verbal ﬂuency¶
Placebo 13.5  0.1 12.3  1.0 10.8  0.9 0.318 0.007 0.307
Glucose 13.3  0.9 11.7  0.8 11.6  0.9
Stroop word
Placebo 103.5  3.8 97.5  3.8 95.5  1.8 0.129 0.004 0.084
Glucose 103.7  1.6 105.2  1.3 102.3  2.3
Stroop color
Placebo 77.5  2.5 78.5  2.8 59.0  0.7 0.014 0.001 0.011
Glucose 77.1  1.5 79.2  1.3 71.5  1.8**
Stroop color-words
Placebo 51.6  1.3 51.5  0.8 44.0  0.3 0.862 0.001 0.003
Glucose 49.6  1.9 50.7  2.1 47.0  1.6**
Verbal memory test††
Placebo 5.0  0.1 5.0  0.1 3.5  0.4 0.318 0.007 0.307
Glucose 5.0  0.1 4.3  0.4 3.2  0.5
Data are means  SE. P values are calculated from repeated-measures ANOVA. **P  0.05 vs. placebo; *time (s) required to complete the
task; †number of correct responses; ‡number of digit sequences correctly repeated; §number of correct targets crossed out in 90 s; ¶number
of words named in 60 s; number of correct responses in 45 s; ††number of words recalled.
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humans (5–7). However, only one study aimed at preven-
tion of portal hypoglycemia after administration of 20 g
oral glucose (6). In contrast to our study, Smith et al. (6)
reported a slightly lower response of adrenaline early after
oral glucose. However, the effect was modest and not
conﬁrmed over the entire hypoglycemic plateau (6). In the
present study, greater oral glucose (28 g) given earlier than
in Smith study and in a model of slow-fall hypoglycemia to
prevent portal hypoglycemia had no effects.
The two other studies (5,7) do not explore the role of
portal-hepatic glucose sensors during slow-fall hypoglyce-
mia. In fact hypoglycemia was induced quickly in both
studies (5,7): respectively 2–4 and 1.3 mg  dl
1 
min
1. In addition, in one study (5) oral glucose was given
after, not before, induction of hypoglycemia; in the other
study (7), a small amount of carbohydrates as orange juice
(15 g), not glucose, was given, and calculations of esti-
mated portal plasma glucose were not performed.
In conclusion, the results of the present study indicate
that ingestion of oral glucose to prevent portal hypoglyce-
mia from an early phase of slow-fall systemic hypoglyce-
mia does not affect responses of counterregulatory
hormones and symptoms to hypoglycemia. Thus, in con-
trast to rats (25), the putative portal glucose sensors in
humans do not play an appreciable role in modulating
these responses to hypoglycemia, at least in the clinically
relevant condition of slow-fall hypoglycemia. In humans,
portal glucose sensors likely have a role different from that
in animals (14,15,23–25). Additional studies are required to
explore the complex potential of portal glucose sensors in
glucose homeostasis in humans.
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